News

Study claims GMO cancer risk
Enlarge image

PolicyEUUKFranceSpain

Study claims GMO cancer risk

21.09.2012 - Researchers from the organisation Criigen have published a GMO feeding study suggesting a cancer risk in mice. Critics say the study design was not appropriate.

In the peer reviewed journal Food and Chemical Toxicology a team headed by Criigen president Gilles-Eric Seralini report that lab mice fed with Monsanto’s GM maize NK603 or with the herbicide Glyphosate developed faster tumours than control mice. While treated female rats died 2-3 fold more frequently than controls, male rats which received the GMO or herbicide diet over 2 years developed tumours, which were up to 4 times larger than in control mice and occurred earlier in their life cycle, accompanied by kidney defects in both sexes.

However, critics questioned the credibility and reliability of the data. "The methods, stats and reporting of results are all well below the standard I would expect in a rigorous study – to be honest I am surprised it was accepted for publication“, stated Prof. Dr. David Spiegelhalter from University of Cambridge, UK, explaining that there was no full data set, no relevant number of animals involved to demonstrate statistical significance and no dose-dependent effect confirming the conclusions of the study authors. Prof. Dr. Maurice Moloney, chief of Rothamsted Research, pointed to the fact that the rat species used by the French researchers is extremely susceptible to developing spontaneous cancers, with up to 86% in wild-type males and 72% in normal females. According to Dr. Wendy Harwood, John Innes Centre, „without access to the full data, we can only say that these results cannot be interpreted as showing that GM technology itself is dangerous.“ Some researchers also criticised that it was not good scientific practice to give the data to the press before making them public to the scientific community. Others such as Prof. Dr. Jose Miquel Mulet from University of Valencia presumed the study was politically motivated: The reports of Criigen are put forward by the French authorities as justification to maintaining bans on cultivating GMOs,“he stressed. French Prime Minister Jean-Marc Ayrault stated in Paris: "The government is keeping its moratorium on the cultivation of GMO seeds currently authorised in the European Union." 

A spokesman of the European Food watchdog EFSA said it will consider the paper’s relevance (http://www.efsa.europa.eu/en/press/news/120919b.htm). The study appears as a direct attack on the EFSA’s methods. However, recently, an independent study carried out by Ernst & Young confirmed the agency’s assessments had excellent scientific quality.  

Since the foundation of Criigen in 2001, its researchers have questioned the design of animal studies used to assess GMO safety. The organisation is financed through contract research . Although its researchers carry out contract studies for Greenpeace and Carrefour, the large French food retailer which claims its products to be GM-free, its researchers say the organisation is independent.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-03/study-claims-gmo-cancer-risk.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SCANCELL HOLDINGS (UK)29.25 GBP7.93%
  • CELLECTIS (F)32.30 EUR7.31%
  • ALMIRALL (E)17.87 EUR7.26%

FLOP

  • TRANSGENE (F)3.99 EUR-14.56%
  • BAVARIAN NORDIC (D)39.72 EUR-5.61%
  • EUROFINS SCIENTIFIC (F)255.00 EUR-5.39%

TOP

  • VERONA PHARMA (UK)5.20 GBP24.7%
  • PROTHENA PLC (IE)52.67 USD23.4%
  • DBV Technologies (F)51.87 EUR21.8%

FLOP

  • NORDIC NANOVECTOR (N)26.90 NOK-23.4%
  • NEUROVIVE PHARMACEUTICAL AB (S)20.10 SEK-23.3%
  • OREXO (S)68.00 SEK-22.5%

TOP

  • ADOCIA (F)67.19 EUR384.1%
  • 4SC (D)4.52 EUR334.6%
  • WILEX (D)3.64 EUR333.3%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-75.0%
  • ACTIVE BIOTECH (S)8.60 SEK-70.1%
  • NEOVACS (F)1.12 EUR-67.2%

No liability assumed, Date: 01.07.2015